Company / Return on Equity (ROE)
Haemonetics Return on Equity (ROE) History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
17.5%
FY2024
5-year range
5.9% / 17.5%
FY2020-FY2024
Trend
+21.6%
vs FY2023
Sector context
#25 of 147
Health Care
What the data says
Haemonetics's return on equity (roe) of 17.5% is higher than 83% of companies in the Health Care sector (FY2024). Return on Equity (ROE) has fluctuated over the past 9 years, ranging from -3.6% in FY2016 to 17.5% in FY2024.
Based on SEC 10-K filings.
17.5% in FY2024 with a 5-year CAGR of +6.0%. Top quartile in the Health Care sector.
Improved from 15.4% to 17.5% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +11.5pp
- 5-Year Change
- +6.0pp
- 10-Year Change
- -
Sector benchmark
+674.3% above sector average
Key checks
Key Insights
- In FY2024, return on equity (roe) increased 21.6% year-over-year.
- Currently 20.5pp above the Health Care sector average.
- Lowest return on equity (roe) in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | 17.5% | +21.6% |
| FY2023 | 14.4% | -6.7% |
| FY2022 | 15.4% | +159.7% |
| FY2021 | 5.9% | -56.2% |
| FY2020 | 13.5% | +18.2% |
| FY2019 | 11.5% | +56.8% |
| FY2018 | 7.3% | +18.7% |
| FY2017 | 6.2% | +269.2% |
| FY2016 | -3.6% | +45.9% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026